$LXRX News

Lexicon Pharmaceuticals: Uncertainty Clouds The Bull Case (Rating Downgrade)

Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Lexicon Pharmaceuticals (LXRX) Is Up 46.1% After Revenue Surges And Loss Narrows Sharply – What's Changed

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.1

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon Pharmaceuticals (NASDAQ:LXRX) Q1 2026 Results Show Revenue Beat and Narrowed Loss

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Q1 Sales $1.090M Miss $9.380M Estimate

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

Novo Nordisk Extends Pipeline With Semaglutide Alcohol Study And LX9851 Trial

Lexicon Pharma (LXRX), Novo Nordisk (NVO) Initiate Phase 1 Study for Obesity Drug LX9851

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

How The Lexicon Pharmaceuticals (LXRX) Investment Story Is Shifting With Pilavapadin And LX9851

Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin Data

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

Lexicon Pharmaceuticals To Present Data From Its PROGRESS Phase 2b Trial Of Pilavapadin In Diabetic Peripheral Neuropathic Pain To Support Selection Of Pilavapadin 10 Mg As Optimal Dose For Phase 3 Development

How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting Around Pilavapadin And Valuation Assumptions